Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Phase I-II, randomized, open-label, multicenter, international clinical trial Patients with
advanced soft-tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, alveolar
soft-part sarcoma) and osteosarcoma will receive selinexor in combination with gemcitabine.